This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease–if they keep current with developments in drug therapy. Address comments to Patricia A. Howard, PharmD, Professor and Vice Chair, Pharmacy Practice, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160-7231. E-mail: phoward@kumc.edu.
MukherjeeD., NissenS.E., TopolE.J.Risk of cardiovascular events associated with selective COX-2 inhibitors.JAMA.2001; 286; 954–9.
3.
SanmuganathanP.S., GhahramaniP., JacksonP.R.Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.Heart.2001; 85: 265–71.
4.
US Prevention Services Task Force.Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale.Ann Intern Med.2002; 136: 157–60.
5.
Antiplatelet Trialists' Collaboration.Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.Br Med J.1994; 308: 81–106.
6.
RyanT.J., AntmanE.M., Brooks1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines (Committee on Management of Acute Myocardial Infarction).J Am Coll Cardiol.1999; 34: 890–911.
7.
Catella-LawsonF., ReillyM.P., KapoorS.C.Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.N Engl J Med.2001; 345: 1809–17.
8.
VaneJr, BottingR.M.Mechanism of action of nonsteroidal anti-inflammatory drugs.Am J Med.1998; 104(3A): 2S–8S.
9.
CryerB., FeldmanM.Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.Am J Med.1998; 104: 413–21.
10.
GumP.A., Kottke-MarchantK., PoggioE.D.Profile and prevalence of aspirin resistance in patients with cardiovascular disease.Am J Cardiol.2001; 88: 230–5.
BombardierC., LaineL., ReicinA. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med.2000; 343: 1520–8.
13.
SilversteinF.E., FaichG., GoldsteinJ.L.for the Celecoxib Long-term Arthritis Safety Study: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial.JAMA.2000; 284: 1274–55.
14.
KonstamM.A., WeirM.R., ReicinA.Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.Circulation.2001; 104: 2280–8.
15.
ReicinA.S., ShapiroD., SperlingR.S.Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib vs nonselective nonsteroidal antiinflamamtory drugs (ibuprofen, diclofenac, and nabumetone).Am J Cardiol.2002; 89: 204–9.
16.
SolomonD.H., GlynnR.J., LevinR.Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.Arch Intern Med.2002; 162: 1099–104.
17.
WatsonD.J., RhodesT., CaiB.Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.Arch Intern Med.2002; 162: 1105–10.
18.
RahmeE., PiloteL., LeLorierJ.Association between naproxen use and protection against acute myocardial infarction.Arch Intern Med.2002; 162: 1111–5.
19.
RayW.A., SteinC.M., HallK.Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study.Lancet.2002; 359: 118–23.
ChengY., AustinS.C., RoccaB.Role of prostacyclin in the cardiovascular response to thromboxane A2.Science.2002; 296: 539–41.
22.
DeMariaA.N.Relative risk of cardiovascular events in patients with rheumatoid arthritis.Am J Cardiol.2002; 89(suppl): 33D–38D.
23.
LipaniJ.The data are inconclusive and these drugs are needed.Cleve Clin J Med.2001; 68: 961–2.
24.
VanHeckenA., SchwartzJ.I., DepreM.Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 vs COX-1 in healthy volunteers.J Clin Pharmacol.2000; 40: 1109–20.
